Evidence map›Paper›PMID 37876893›Full record

ArticleRadiology case reports2023

Complete response of glottic cancer to intra-arterial infusion chemotherapy combined with radiotherapy: A report of 4 cases.

Ryo Yamakuni, Hirofumi Sekino, Masakazu Ikeda, Yoshiki Endo, Masamitsu Ikeda, Shiro Ishii, Kenji Fukushima, Shigeyuki Murono, Yoshiyuki Suzuki, Hiroshi Ito

Open access · goldAbstract readCase Reports
In one paragraph

Article in Radiology case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ryo YamakuniDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hirofumi SekinoDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Masakazu IkedaDepartment of Otorhinolaryngology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yoshiki EndoDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Masamitsu IkedaDepartment of Radiology, Fukushima Medical University Hospital, Fukushima, Japan.
Shiro IshiiDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kenji FukushimaDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shigeyuki MuronoDepartment of Otorhinolaryngology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yoshiyuki SuzukiDepartment of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hiroshi ItoDepartment of Radiology and Nuclear Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection is recommended for advanced-stage, resectable glottic cancer. However, total laryngectomy results in the loss of vocal function and reduces patients' quality of life. At our institution, patients with cT3N0M0 stage III resectable glottic cancer who wish to preserve their larynx are treated with super-selective cisplatin infusion with concomitant radiotherapy (RADPLAT) to improve local control over systemic chemotherapy. Herein, we present 4 patients with glottic cancer who underwent biweekly intra-arterial infusion chemotherapy combined with radiation therapy 3 times. For intra-arterial infusion chemotherapy, 100 mg cis-diaminodichloroplatinum was infused into the superior thyroid artery, including the superior laryngeal artery branch. Thereafter, intensity-modulated radiation therapy was administered at doses of 70 Gy in 35 fractions for 3 patients and 66 Gy in 33 fractions for 1 patient. These patients showed complete response after chemoradiotherapy with no recurrence or metastases during the follow-up period to date (mean follow-up period: 56 months, range: 39-76 months).

Indexed as

Functional preservationGlottic cancerIntra-arterial infusion chemotherapyLaryngeal cancerRadiotherapySuper-selective cisplatin infusion with concomitant radiotherapy (RADPLAT)

Identifiers

PMID37876893
PMCPMC10590759
OpenAlexW4387630189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.